10780432ccr112240-sup-relatedarticle.html (0.76 kB)

Related Article from Is It Downhill from Here? Eliminating Leukemic Stem Cells and Curing Chronic Myeloid Leukemia

dataset

posted on 2023-03-31, 16:54 authored by Catherine C. Smith, Neil P. Shah

History

ARTICLE ABSTRACT

Patients with chronic phase chronic myeloid leukemia who respond to imatinib have a rapid initial decrease in BCR-ABL transcript levels (α), followed by a slow decline (β). The rate of β decrease is consistent with declining leukemic stem cells and may predict which patients may safely discontinue therapy. Clin Cancer Res; 17(21); 6605–7. ©2011 AACR.